Within this context, Lillys meticulous R&D strategy and market execution have paid off: Mounjaro and ZepBound are generating record sales, and Lillys pipeline is deep with next-generation incretin candidates
for $4.9 billion, gaining access to Metsera's promising GLP-1 pipeline, including oral and injectable formulations
The rates and severity of these AEs vary by agent, formulation, and dosing schedule
No matter your reason for taking a GLP-1whether for blood sugar control, weight management, or to reduce the risk of heart diseaseits possible to develop a sick-to-the-stomach feeling while on the drug
This also shifted GLP-1 therapy from being purely a metabolic medication to a cardiovascular diseasemodifying therapy, even in patients without diabetes
Zealand Pharma